QQ客服 官方微博 反馈留言

	Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study
	Fennell, Dean A.; Baas, Paul; Taylor, Paul; Nowak, Anna K.; Gilligan, David; Nakano, Takashi; Pachter, Jonathan A.; Weaver, David T.; Scherpereel, Arnaud; Pavlakis, Nick
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2019
卷号	37期号:10
ISSN号	0732-183X
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3413507
专题	昆明医科大学
推荐引用方式 GB/T 7714	Fennell, Dean A.,Baas, Paul,Taylor, Paul,et al. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study[J]. JOURNAL OF CLINICAL ONCOLOGY,2019,37(10).
APA	Fennell, Dean A..,Baas, Paul.,Taylor, Paul.,Nowak, Anna K..,Gilligan, David.,...&Aerts, Joachim G. J. V..(2019).Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.JOURNAL OF CLINICAL ONCOLOGY,37(10).
MLA	Fennell, Dean A.,et al."Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study".JOURNAL OF CLINICAL ONCOLOGY 37.10(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。